Sudarshan Pharma Hyderabad Unit Secures GMP Compliance and ISO 9001 Certification for API Production

Sudarshan Pharma Industries Limited said its Hyderabad, Telangana, unit received key global certifications. The company told stock exchanges on Wednesday that quality controls were strengthened. The certificates cover API Intermediates and Active Pharmaceutical Ingredients (APIs). Both approvals remain valid until February 11, 2029, with surveillance audits required.

In market trade, Sudarshan Pharma Industries Ltd (BSE: 543828) was at Rs 26.00 by 1:30 PM IST on February 19, 2026. The price was up 1.25% from the previous close. The 52-week range stood between Rs 18.50 and Rs 35.40. Market value was about Rs 625.71 Crore.

The Hyderabad facility sits in IDA-Medchal and makes APIs and API Intermediates. UK Certification & Inspection Limited granted a Certificate of Compliance for Good Manufacturing Practice (GMP). The firm said this showed alignment with recognised GMP guidelines. The review covered quality checks, standard processes, and documentation for consistent output.

Separately, Staunchly Management and System Services Private Limited confirmed ISO 9001:2015 compliance. This ISO certificate also applies to API and API Intermediate production. The company said the system focuses on efficiency, risk handling, and ongoing improvement. Both certifications require periodic checks through surveillance audits during the validity period.

Item	Detail
Shares traded	About 104,000
Open	Rs 25.50
Intraday range	Rs 25.40 to Rs 26.13
50-DMA	Rs 23.83
200-DMA	Rs 27.54

Founded in 2008, Sudarshan Pharma Industries Limited is headquartered in Mumbai. The company is ISO-certified and works across APIs, specialty chemicals, and generic pharmaceutical formulations. It operates in India and overseas markets. Exports listed include the UK, Australia, Uzbekistan, Syria, Oman, Taiwan, and MENA regions.

The company also supplies generic formulations and medicines to institutions. These include hospitals, government agencies, non-governmental organisations, and other healthcare bodies. It does this through contract manufacturing, outsourcing, and supply arrangements. Dhan data showed an intraday upswing, above the 50-DMA. The price stayed below the 200-DMA.